Serum 1,25-dihydroxyvitamin d and the development of kidney dysfunction in a Japanese community: The hisayama study

Circulation Journal

Volumn 78, Issue 3, 2014, Pages 732-737

  Izumaru, Kensuke ^a   Ninomiya, Toshiharu ^a   Nagata, Masaharu ^a   Usui, Tomoko ^a   Yoshida, Daigo ^a   Yonemoto, Koji ^a   Fukuhara, Masayo ^a   Tsuruya, Kazuhiko ^a   Kitazono, Takanari ^a   Kiyohara, Yutaka ^a,b  

^a KYUSHU UNIVERSITY   (Japan)

^b KURUME UNIVERSITY   (Japan)

Author keywords

1,25 dihydroxyvitamin D; Chronic kidney disease; Epidemiology; Glomerular filtration rate

Indexed keywords

CALCITRIOL;

ADULT; ALBUMINURIA; ARTICLE; ASIAN; CHRONIC KIDNEY DISEASE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; JAPAN; MALE; MIDDLE AGED; PROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY ANALYSIS; VITAMIN D DEFICIENCY; AGE; AGED; BLOOD; CLINICAL TRIAL; COMPLICATION; KIDNEY DISEASES; MULTICENTER STUDY; SEX DIFFERENCE;

AGE FACTORS; AGED; CALCITRIOL; FOLLOW-UP STUDIES; HUMANS; JAPAN; KIDNEY DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEX FACTORS; VITAMIN D DEFICIENCY;

EID: 84894472852     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-0422     Document Type: Article

References (38)

1. Just PM, de Charro FT, Tschosik EA, Noe LL, Bhattacharyya SK, Riella MC. Reimbursement and economic factors influencing dialysis modality choice around the world. Nephrol Dial Transplant 2008; 23: 2365-2373.
2. Khan S, Amedia CA Jr. Economic burden of chronic kidney disease. J Eval Clin Pract 2008; 14: 422-434.
3. Meguid El, Nahas A, Bello AK. Chronic kidney disease: The global challenge. Lancet 2005; 365: 331-340.
4. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: Effects on the cardiovascular system. Circulation 2007; 116: 85-97.
5. Dan K, Miyoshi T, Ueeda M, Ohtsuka H, Ugawa S, Ohnishi N, et al. Impact of chronic kidney disease on left main coronary artery disease and prognosis in Japanese patients. Circ J 2012; 76: 2266-2272.
6. Ueshima K, Oba K, Yasuno S, Fujimoto A, Tanaka S, Ogihara T, et al. Influence of coronary risk factors on coronary events in Japanese high-risk hypertensive patients. Primary and secondary prevention of ischemic heart disease in a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. Circ J 2011; 75: 2411-2416.
7. Kawai H, Sarai M, Motoyama S, Harigaya H, Ito H, Sanda Y, et al. Coronary plaque characteristics in patients with mild chronic kidney disease: Analysis by 320-row area detector computed tomography. Circ J 2012; 76: 1436-1441.
8. Nakajima K, Nishimura T. Cardiovascular events in Japan. Lessons from the J-ACCESS multicenter prognostic study using myocardial perfusion imaging. Circ J 2012; 76: 1313-1321.
9. Alexander M, Bradbury BD, Kewalramani R, Barlev A, Mohanty SA, Globe D. Chronic kidney disease and US healthcare resource utilization in a nationally representative sample. Am J Nephrol 2009; 29: 473-482.
10. Martins D, Agodoa L, Norris K. Kidney disease in disadvantaged populations. Int J Nephrol 2012; 2012: 469265, doi:10.1155/2012/469265.
11. Goolsby MJ. National kidney foundation guidelines for chronic kidney disease: Evaluation, classification, and stratification. J Am Acad Nurse Pract 2002; 14: 238-242.
12. Doorenbos CR, van den Born J, Navis G, de Borst MH. Possible renoprotection by vitamin D in chronic renal disease: Beyond mineral metabolism. Nat Rev Nephrol 2009; 5: 691-700.
13. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005; 289: F8-F28.
14. Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, et al. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med 2008; 168: 1340-1349.
15. Jenab M, Bueno-de-Mesquita HB, Ferrari P, van Duijnhoven FJ, Norat T, Pischon T, et al. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: A nested case-control study. BMJ 2010; 340: b5500.
16. Ginde AA, Mansbach JM, Camargo CA Jr. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med 2009; 169: 384-390.
17. Nicholson I, Dalzell AM, El-Matary W. Vitamin D as a therapy for colitis: A systematic review. J Crohns Colitis 2012; 6: 405-411.
18. de Boer IH, Katz R, Chonchol M, Ix JH, Sarnak MJ, Shlipak MG, et al. Serum 25-hydroxyvitamin D and change in estimated glomerular filtration rate. Clin J Am Soc Nephrol 2011; 6: 2141-2149.
19. Melamed ML, Astor B, Michos ED, Hostetter TH, Powe NR, Muntner P. 25-hydroxyvitamin D levels, race, and the progression of kidney disease. J Am Soc Nephrol 2009; 20: 2631-2639.
20. Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2009; 75: 88-95.
21. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, et al. Associations of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations with death and progression to maintenance dialysis in patients with advanced kidney disease. Am J Kidney Dis 2012; 60: 567-575.
22. Ohmura T, Ueda K, Kiyohara Y, Kato I, Iwamoto H, Nakayama K, et al. Prevalence of type 2 (non-insulin-dependent) diabetes mellitus and impaired lucose tolerance in the Japanese general population: The Hisayama Study. Diabetologia 1993; 36: 1198-1203.
23. Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, et al. Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: The Hisayama Study. Stroke 2003; 34: 2349-2354.
24. Maebuchi D, Arima H, Ninomiya T, Yonemoto K, Kubo M, Doi Y, et al. Arterial stiffness and QT interval prolongation in a general population: The Hisayama Study. Hypertens Res 2008; 31: 1339-1345.
25. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
26. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1-S266.
27. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089-2100.
28. Mitsuhashi T, Morris RC Jr, Ives HE. 1,25-dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. J Clin Invest 1991; 87: 1889-1895.
29. Motiwala SR, Wang TJ. Vitamin D and cardiovascular risk. Curr Hypertens Rep 2012; 14: 209-218.
30. Choi SW, Kim HY, Lee YH, Ryu SY, Kweon SS, Rhee JA, et al. eGFR is associated with subclinical atherosclerosis independent of albuminuria: The Dong-gu Study. Atherosclerosis 2010; 212: 661-667.
31. Hermans MM, Henry R, Dekker JM, Kooman JP, Kostense PJ, Nijpels G, et al. Estimated glomerular filtration rate and urinary albumin excretion are independently associated with greater arterial stiffness: The Hoorn Study. J Am Soc Nephrol 2007; 18: 1942-1952.
32. Zou MS, Yu J, Zhou JH, Nie GM, Ding DS, Luo LM, et al. 1,25-dihydroxyvitamin D3 ameliorates podocytopenia in rats with adriamycin- induced nephropathy. Intern Med 2010; 49: 2677-2686.
33. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E. Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 1998; 53: 1696-1705.
34. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2006; 17: 3382-3393.
35. Zhang Y, Kong J, Deb DK, Chang A, Li YC. Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. J Am Soc Nephrol 2010; 21: 966-973.
36. Kuhlmann A, Haas CS, Gross ML, Reulbach U, Holzinger M, Schwarz U, et al. 1,25-dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004; 286: F526-F533.
37. Craver L, Marco MP, Martinez I, Rue M, Borras M, Martin ML, et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5: Achievement of K/DOQI target ranges. Nephrol Dial Transplant 2007; 22: 1171-1176.
38. Andress DL. Vitamin D in chronic kidney disease: A systemic role for selective vitamin D receptor activation. Kidney Int 2006; 69: 33-43.